Eisenkraft Klein Daniel, Schouten Arianna
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
BMJ Glob Health. 2025 Sep 2;10(9):e018783. doi: 10.1136/bmjgh-2024-018783.
The Canadian federal government has consistently emphasized its commitment to global health equity. However, during the COVID-19 pandemic and its aftermath, Canada repeatedly resisted measures designed to promote equitable and timely global access to medicines through intellectual property (IP) sharing. This research study employs a qualitative, document-based thematic analysis to examine how Canada's rhetorical commitments to equity intersected with its policy actions across three key cases: Canada's Patent Act flexibilities surrounding the COVID-19 World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Waiver; Bolivia and Biolyse's efforts to navigate Canada's Access to Medicines Regime and the World Health Assembly's intergovernmental negotiating body's efforts to draft a treaty for pandemic prevention, preparedness and response. Across these cases, we find that Canadian representatives strategically advanced a narrow conception of equity centred on inclusion and gender, while sidelining intellectual property reform and the structural conditions of access. We conclude by outlining three policy recommendations for Canada to better align its commitment to equity with action on encouraging access to life-saving medicines.
加拿大联邦政府一直强调其对全球卫生公平的承诺。然而,在新冠疫情期间及其余波中,加拿大屡次抵制旨在通过知识产权共享促进全球公平、及时获取药品的措施。本研究采用基于文件的定性主题分析方法,考察加拿大在三个关键案例中对公平的言辞承诺如何与其政策行动相互交织:围绕新冠疫情世界贸易组织《与贸易有关的知识产权协定》豁免,加拿大《专利法》的灵活性;玻利维亚和Biolyse公司在加拿大药品获取制度中的周旋;以及世界卫生大会政府间谈判机构为起草大流行预防、防范和应对条约所做的努力。在这些案例中,我们发现加拿大代表策略性地推进了一种狭隘的公平概念,该概念以包容性和性别为核心,同时将知识产权改革和获取药品的结构性条件边缘化。我们最后为加拿大概述了三项政策建议,以使其对公平的承诺更好地与鼓励获取救命药品的行动保持一致。